Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

62.69USD
25 Sep 2020
Change (% chg)

$0.44 (+0.71%)
Prev Close
$62.25
Open
$61.85
Day's High
$63.50
Day's Low
$60.87
Volume
113,103
Avg. Vol
154,157
52-wk High
$78.69
52-wk Low
$26.56

Latest Key Developments (Source: Significant Developments)

Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results And Recent Business Developments
Friday, 8 May 2020 

May 7 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $2.39.Q1 EARNINGS PER SHARE ESTIMATE $-2.34 -- REFINITIV IBES DATA.Q1 LOSS PER SHARE $3.07.  Full Article

Biohaven Enters Deal With Genpharm For Distribution Of NURTEC ODT In The Middle East
Monday, 27 Apr 2020 

April 27 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ENTERS INTO AGREEMENT WITH GENPHARM FOR DISTRIBUTION OF NURTEC™ ODT IN THE MIDDLE EAST.BIOHAVEN PHARMACEUTICAL - AGREEMENT BETWEEN BIOHAVEN, GENPHARM INCLUDES NURTEC ODT, APPROVED IN USA ON FEB 27 FOR ACUTE TREATMENT OF MIGRAINE.  Full Article

Biohaven Enters Into Partnership With Medison Pharma To Distribute Nurtec Odt In Israel
Thursday, 16 Apr 2020 

April 16 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN - ENTERS INTO PARTNERSHIP WITH MEDISON PHARMA TO DISTRIBUTE NURTEC ODT IN ISRAEL.BIOHAVEN - REGISTRATION IN ISRAEL BASED UPON BIOHAVEN'S NURTEC ODT APPROVAL IN U.S..  Full Article

Biohaven's Nurtec ODT (Rimegepant) Receives FDA Approval For Acute Treatment Of Migraine In Adults
Friday, 28 Feb 2020 

Feb 27 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN'S NURTEC™ ODT (RIMEGEPANT) RECEIVES FDA APPROVAL FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS.  Full Article

Kleo Pharmaceuticals Receives IND Authorization To Proceed From FDA For Its Multiple Myeloma Therapeutic
Thursday, 6 Feb 2020 

Feb 6 (Reuters) - Kleo Pharmaceuticals Inc::KLEO PHARMACEUTICALS RECEIVES IND AUTHORIZATION TO PROCEED FROM FDA FOR ITS MULTIPLE MYELOMA THERAPEUTIC.KLEO PHARMACEUTICALS - TRIAL IS EXPECTED TO BEGIN ENROLLMENT IN FIRST HALF OF 2020, TOPLINE DATA ARE EXPECTED IN SECOND HALF OF 2021.  Full Article

Biohaven Says Public Offering Of Common Shares Priced At $51.75/Shr
Wednesday, 29 Jan 2020 

Jan 29 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PRICING OF $250 MILLION PUBLIC OFFERING OF COMMON SHARES.BIOHAVEN PHARMACEUTICAL HOLDING - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4.8 MILLION OF COMMON SHARES AT PRICE TO PUBLIC OF $51.75 PER SHARE.  Full Article

Biohaven Announces Proposed Public Offering Of Common Shares
Wednesday, 29 Jan 2020 

Jan 28 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $250 MILLION OF ITS COMMON SHARES.  Full Article

Biohaven Achieves Positive Topline Results In Pivotal Phase 2/3 Study Of Vazegepant
Tuesday, 17 Dec 2019 

Dec 17 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ACHIEVES POSITIVE TOPLINE RESULTS IN PIVOTAL PHASE 2/3 STUDY OF VAZEGEPANT, THE FIRST AND ONLY INTRANASAL CGRP RECEPTOR ANTAGONIST IN CLINICAL DEVELOPMENT FOR THE ACUTE TREATMENT OF MIGRAINE.BIOHAVEN PHARMACEUTICAL - ADDITIONAL RESULTS FROM PHASE 2/3 STUDY OF VAZEGEPANT ANTICIPATED TO BE PRESENTED AT UPCOMING SCIENTIFIC MEETINGS IN 2020.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - VAZEGEPANT MET CO-PRIMARY ENDPOINTS OF PAIN FREEDOM & FREEDOM FROM MOST BOTHERSOME SYMPTOM.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - LEAD PRODUCT RIMEGEPANT ZYDIS ODT IS UNDER FDA REVIEW WITH A Q1 2020 PDUFA DATE.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - VAZEGEPANT WAS ALSO SUPERIOR TO PLACEBO ON MULTIPLE SECONDARY ENDPOINTS DEMONSTRATING EARLY ACTIVITY.  Full Article

Biohaven's Troriluzole Advances Past Interim Futility Analysis In Phase 2/3 Alzheimer's Disease Study
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN'S TRORILUZOLE SUCCESSFULLY ADVANCES PAST INTERIM FUTILITY ANALYSIS IN PIVOTAL PHASE 2/3 ALZHEIMER'S DISEASE STUDY.BIOHAVEN PHARMACEUTICAL HOLDING CO - DSMB COMPLETED ITS REVIEW OF PRESPECIFIED INTERIM FUTILITY ANALYSIS AND COMMUNICATED THAT FUTILITY WAS NOT MET.BIOHAVEN PHARMACEUTICAL - CO IS ENCOURAGED BY ADVANCING PAST PRESPECIFIED FUTILITY CRITERIA AFTER FIRST 100 PATIENTS COMPLETED 6 MONTHS OF TREATMENT.  Full Article

Biohaven Posts Q3 Loss Of $2.04/Shr
Saturday, 2 Nov 2019 

Nov 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS.Q3 LOSS PER SHARE $2.04.Q3 EARNINGS PER SHARE ESTIMATE $-1.57 -- REFINITIV IBES DATA.EXPECTED PDUFA DATE OF Q1 OF 2020 FOR ZYDIS ORALLY DISSOLVING TABLET FORMULATION.CASH AS OF SEPTEMBER 30, 2019, WAS $416.6 MILLION, COMPARED TO $465.7 MILLION AS OF JUNE 30, 2019.  Full Article